| Title: | Barr Pharmaceuticals Inc. |
| Price: | $400.00 |
| Publication Date: | May 01, 2008 |
| Report Type: | Full Report |
| Abstract: | Solid position in the growing generic drug industry; Productive product pipeline with track record of capitalizing on 180-day exclusivity opportunities; and A significant oral contraceptives franchise that has enabled Barr to generate higher-than-average gross margins. The oral contraceptives market, which accounts for nearly 30% of Barr's revenues, is attracting more competitors; and The generics industry continues to be fiercely competitive, with still relatively low barriers to entry. The low investment-grade rating on Woodcliff Lake, N.J.-based Barr Pharmaceuticals Inc. reflects its strong position in the growing generic drug industry, continued free cash flows, and its established conservative financial policies. These factors are somewhat mitigated by the high level of competition in the company's core generic drug and oral contraceptives markets. Barr's |
| Brief Excerpt: | RESEARCH Ratings Definitions Barr Pharmaceuticals Inc. Publication date: ##-May-#### Primary Credit Analyst: Arthur Wong, New York (#) ###-###-####; arthur_wong@standardandpoors.com Major Rating Factors Corporate Credit Rating ###-/Stable/--... |
| Word Count: | 2012 |
| Ticker: | BRL |
| Issuer: | Barr Pharmaceuticals Inc. |
| GICS: | Pharmaceuticals (35202010) |
| Sector: | Global Issuers, Corporations, Health Care |
| Country: | United States |
| Region: | United States |
| Format: | 
HTML
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?
